Supernus Pharmaceuticals | SUPN - 销售和管理费用

金融业

USD

USD 1.5B

现金及等价物

USD 184.87M

USD 49.04M

USD 731.58M

USD 373.93M

USD 40.98M

USD -35.25M

USD 29.23M

674

EPS每股收益

USD 0.6

股本和储备

USD 1.08B

USD 129.36M

债务利息支出

USD 910K

USD 2.02M

USD 400.38M

USD 2.67B

USD -2.29M

USD 1.08B

USD -35.25M

普通股股本

USD 58.04M

44.21

USD -5.95M

USD 207.71M

销售和管理费用

USD 118.23M

USD 110.77M

贸易债权人

USD 10.17M

应收帐款人

USD 182.18M

	销售和管理费用	更改		日
Abbott	USD 3.27B		138M	2026-03
ANI Pharmaceuticals	USD 73.66M		9.14M	2026-03
Aurora Cannabis	CAD 41.4M		781K	2026-03
Bristol-Myers Squibb	USD 1.62B		564M	2026-03
Canopy Growth	CAD 31.17M		2.27M	2026-03
Cara Therapeutics	USD 2.19M		2.45M	2025-09
Corcept Therapeutics	USD 128.04M		13.3M	2026-03
Eisai	JPY 119.54B		7.82B	2026-03
Eli Lilly	USD 2.93B		198M	2026-03
Novo Nordisk	DKK 13.22B		4.22B	2026-03
Pacira	USD 83.88M		7.99M	2026-03
Perrigo	USD 267.3M		11.4M	2026-03
Pfizer	USD 2.92B		1.16B	2026-03
Supernus Pharmaceuticals	USD 118.23M		4.16M	2026-03
United Therapeutics	USD 156.6M		34M	2026-03
Xeris Pharmaceuticals	USD 53.14M		10.51M	2026-03